Cite

HARVARD Citation

    Li, Y. et al. (2020). Is nab-paclitaxel better than conventional taxanes as neoadjuvant therapy for breast cancer? A meta-analysis. Journal of international medical research. 48 (8), p. . [Online]. 
  
Back to record